Rapamycin: A rheostat for CD8+ T-cell-mediated tumor therapy

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1189-1190

  Srivastava, Rupesh K ^a   Utley, Adam ^a   Shrikant, Protul A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer; Memory CD8+ T cells; mTOR; Rapamycin; Vaccine

Indexed keywords

BCG VACCINE; CANCER VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ARTICLE; CANCER IMMUNIZATION; CANCER THERAPY; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; TUMOR IMMUNITY;

EID: 84877057592     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20663     Document Type: Article

References (10)

1. Zinkernagel RM. Immunology taught by viruses. Science 1996; 271:173-8; PMID:8539616; http://dx.doi.org/10.1126/science.271.5246.173.
2. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010; 32:67-78; PMID:20060330; http://dx.doi.org/10.1016/j.immu-ni.2009.10.010.
3. Araki K, Turner A P, Shaffer VO, Gangappa S, Keller SA, Bachmann M F, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-12; PMID:19543266; http://dx.doi.org/10.1038/nature08155.
4. + T cell memory and tumor immunity. Immunity 2011; 34:541-53; PMID:21511183; http://dx.doi.org/10.1016/j.immu-ni.2011.04.006.
5. Colombetti S, Basso V, Mueller DL, Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol 2006; 176:2730-8; PMID:16493028.
6. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162:2775-84; PMID:10072524.
7. + regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol 2008; 83:1230-9; PMID:18270248; http://dx.doi.org/10.1189/jlb.1207851.
8. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012; 109:5797-802; PMID:22454499; http://dx.doi.org/10.1073/pnas.1117208109.
9. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, et al. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol 2012; 188:3080-7; PMID:22379028; http://dx.doi.org/10.4049/jimmunol.1103365.
10. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335:1638-43; PMID:22461615; http://dx.doi.org/10.1126/sci-ence.1215135.